A detailed history of Trexquant Investment LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Trexquant Investment LP holds 120,065 shares of VRDN stock, worth $1.84 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
120,065
Previous 142,641 15.83%
Holding current value
$1.84 Million
Previous $3.25 Million 29.09%
% of portfolio
0.03%
Previous 0.04%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

SELL
$17.85 - $25.71 $402,981 - $580,428
-22,576 Reduced 15.83%
120,065 $2.3 Million
Q3 2024

Nov 12, 2024

BUY
$12.16 - $23.33 $1.23 Million - $2.35 Million
100,817 Added 241.05%
142,641 $3.25 Million
Q2 2024

Aug 13, 2024

BUY
$11.6 - $17.26 $485,158 - $721,882
41,824 New
41,824 $544,000
Q4 2022

Feb 13, 2023

BUY
$18.78 - $29.74 $673,957 - $1.07 Million
35,887 New
35,887 $1.05 Million

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $610M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.